A Novel Non-Aqueous Emulsification Platform to Fabricate Polymeric Microspheres for Sustained Delivery of Biologics
Pharmaceutical Research · 2025
DOI: 10.1007/s11095-025-03992-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2025. Verfasst von Nishant S Kulkarni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Formulation Development Group, Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY, USA. nishant.kulkarni@regeneron.com. Hauptthemen laut MEDLINE: Microspheres, Polymers, Biological Products. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Polymeric microspheres (MS) have been developed with moderate success using aqueous emulsification (AqE) for small molecules and peptides with a few approved products. AqE faces a challenge to achieve optimal encapsulation of large hydrophilic molecules such as proteins/mAbs. To overcome this, a novel non-aqueous emulsification platform, "FluoriPack" (FP), was developed. FP is a solid/hydrocarbon/fluorocarbon (S/H/F) platform that enables high biologic loading within MS, with minimal impact on biologic integrity. METHODS: To develop MS using FP, a model protein was encapsulated in polyorthoester (POE) MS via non-aqueous emulsification. The continuous phase was Fluorinert™ FC-40 containing a fluorosurfactant (PicoSurf™ 1). Protein loaded MS were evaluated for morphology, PSD, % loading & in-vitro release (IVR), accelerated stability testing, and toxicity of blank microspheres. Encapsulated protein released from MS were evaluated for integrity and potency. RESULTS: Preliminary evaluation indicates that MS prepared via FP (FP-MS) were superior to AqE-MS, indicated by the surface morphology (non-porous versus porous), encapsulation (> 60% versus 75%). FP-MS had a mean diameter of ~ 40 µm and were stable over 1-month at accelerated conditions. No toxicity was observed in mammalian cells with > 80% viability post FP-MS treatment. The biologic retained integrity post-encapsulation with minimal aggregation (Δ 1.1%) and high potency (> 80%). In vitro release evaluation revealed a sustained release of biologic over 9 days (~ 8% every 24 h). CONCLUSION: MS prepared using FluoriPack achieved the desired quality attributes, enabling it to be a promising tool for sustained delivery of biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Formulation Development Group, Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY, USA. nishant.kulkarni@regeneron.com.
- Formulation Development Group, Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY, USA.
Zitieren
APA
Kulkarni, N. S., James, R., Saraswat, A., Lakshmi, D., Fazily, R., Rayaprolu, B., Chen, H. H., Bhalla, A. S., & Shameem, M. (2025). A Novel Non-Aqueous Emulsification Platform to Fabricate Polymeric Microspheres for Sustained Delivery of Biologics. Pharmaceutical Research. https://doi.org/10.1007/s11095-025-03992-3
Vancouver
Kulkarni NS, James R, Saraswat A, Lakshmi D, Fazily R, Rayaprolu B, et al. A Novel Non-Aqueous Emulsification Platform to Fabricate Polymeric Microspheres for Sustained Delivery of Biologics. Pharmaceutical Research. 2025. doi:10.1007/s11095-025-03992-3
BibTeX
@article{Kulkarni2025,
author = {Kulkarni, Nishant S and James, Roshan and Saraswat, Aishwarya and Lakshmi, Divya and Fazily, Rizan and Rayaprolu, Bindhu and Chen, Hunter H and Bhalla, Amardeep S and Shameem, Mohammed},
title = {A Novel Non-Aqueous Emulsification Platform to Fabricate Polymeric Microspheres for Sustained Delivery of Biologics},
journal = {Pharmaceutical Research},
year = {2025},
doi = {10.1007/s11095-025-03992-3}
}
EUVIMED